What does Farma&Cie do?

Farma&Cie is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 3 January 2017, 1 establishment.

What is the address of Farma&Cie?

The registered office of Farma&Cie is located at Ferdinand Verbiestlaan 41, 2650 Edegem.

Is Farma&Cie still active?

Yes. According to the CBE (16 September 2026) Farma&Cie is active, legal situation “Normale toestand”, started on 3 January 2017.

Is Farma&Cie registered on Peppol?

Yes, Farma&Cie is registered on the Peppol network with ID 0208:0668680188.

What is the enterprise number of Farma&Cie?

The enterprise number of Farma&Cie is BE0668680188.

When was Farma&Cie founded?

Farma&Cie was founded on 3 January 2017.

Who are the directors of Farma&Cie?

According to the 2025 annual accounts, the directors of Farma&Cie are: Carolien Van Assche.

Is Farma&Cie a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 3 January 2017; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Farma&Cie make in 2025?

Farma&Cie posted a profit after taxes of € 140,442 in financial year 2025.

What is the revenue of Farma&Cie?

As a small company, Farma&Cie is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 203,669.

Farma&Cie (Private Limited) - Edegem - BE0668680188

Dossier Farma&Cie, printed on 16 September 2026 from databakkes.be/en/0668680188/farma-cie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 3 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Farma&Cie from Edegem, company number BE0668680188, closed financial year 2025 with a result of € 140,442 after tax. For that financial year Farma&Cie recorded a gross margin of € 203,669 and equity of € 899,986. Compared with financial year 2024, the result moved from € 187,969 to € 140,442. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 17, 2026.

What it is worth Growing

€ 899,986

▲ 18% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 140,442

▼ 25% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 19,760

▼ 76% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 881,386.

Debts at end 2025

Bank debt ≈ 7 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1 million

▼ 20% vs 2024

€ 148,308 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.

Owed to suppliers

€ 579

▼ 18% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 45,338

▼ 50% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 194,111 Gross margin 2022: € 194,111 First fiscal year in the series	€ 253,127 Gross margin 2023: € 253,127 ▲ 30% vs 2022 (€ 194,111) Favourable step	€ 220,358 Gross margin 2024: € 220,358 ▼ 13% vs 2023 (€ 253,127) Unfavourable step	€ 203,669 Gross margin 2025: € 203,669 ▼ 8% vs 2024 (€ 220,358) Unfavourable step	▼ 8%
Profit after taxes	€ 118,076 Profit after taxes 2022: € 118,076 First fiscal year in the series	€ 212,493 Profit after taxes 2023: € 212,493 ▲ 80% vs 2022 (€ 118,076) Favourable step	€ 187,969 Profit after taxes 2024: € 187,969 ▼ 12% vs 2023 (€ 212,493) Unfavourable step	€ 140,442 Profit after taxes 2025: € 140,442 ▼ 25% vs 2024 (€ 187,969) Unfavourable step	▼ 25%
Equity	€ 359,082 Equity 2022: € 359,082 First fiscal year in the series	€ 571,575 Equity 2023: € 571,575 ▲ 59% vs 2022 (€ 359,082) Favourable step	€ 759,544 Equity 2024: € 759,544 ▲ 33% vs 2023 (€ 571,575) Favourable step	€ 899,986 Equity 2025: € 899,986 ▲ 18% vs 2024 (€ 759,544) Favourable step	▲ 18%
Total debts	€ 2,316,441 Total debts 2022: € 2,316,441 First fiscal year in the series	€ 2,194,518 Total debts 2023: € 2,194,518 ▼ 5% vs 2022 (€ 2,316,441) Favourable step	€ 2,070,577 Total debts 2024: € 2,070,577 ▼ 6% vs 2023 (€ 2,194,518) Favourable step	€ 1,792,934 Total debts 2025: € 1,792,934 ▼ 13% vs 2024 (€ 2,070,577) Favourable step	▼ 13%
Cash	€ 12,132 Cash 2022: € 12,132 First fiscal year in the series	€ 89,931 Cash 2023: € 89,931 ▲ € 77,799 vs 2022 (€ 12,132) Favourable step	€ 82,805 Cash 2024: € 82,805 ▼ 8% vs 2023 (€ 89,931) Unfavourable step	€ 19,760 Cash 2025: € 19,760 ▼ 76% vs 2024 (€ 82,805) Unfavourable step	▼ 76%
Retained profit	€ 340,482 Retained profit 2022: € 340,482 First fiscal year in the series	€ 552,975 Retained profit 2023: € 552,975 ▲ 62% vs 2022 (€ 340,482) Favourable step	€ 740,944 Retained profit 2024: € 740,944 ▲ 34% vs 2023 (€ 552,975) Favourable step	€ 881,386 Retained profit 2025: € 881,386 ▲ 19% vs 2024 (€ 740,944) Favourable step	▲ 19%
Bank debt	€ 1,548,827 Bank debt 2022: € 1,548,827 First fiscal year in the series	€ 1,406,173 Bank debt 2023: € 1,406,173 ▼ 9% vs 2022 (€ 1,548,827) Favourable step	€ 1,261,658 Bank debt 2024: € 1,261,658 ▼ 10% vs 2023 (€ 1,406,173) Favourable step	€ 1,015,260 Bank debt 2025: € 1,015,260 ▼ 20% vs 2024 (€ 1,261,658) Favourable step	▼ 20%
Balance sheet total	€ 2,675,523 Balance sheet total 2022: € 2,675,523 First fiscal year in the series	€ 2,766,093 Balance sheet total 2023: € 2,766,093 ▲ 3% vs 2022 (€ 2,675,523) Unchanged	€ 2,830,121 Balance sheet total 2024: € 2,830,121 ▲ 2% vs 2023 (€ 2,766,093) Unchanged	€ 2,692,921 Balance sheet total 2025: € 2,692,921 ▼ 5% vs 2024 (€ 2,830,121) Unchanged	▼ 5%

Key figures of Farma&Cie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Farma&Cie?

What happened at Farma&Cie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 17, 2026 New annual accounts for financial year 2025: profit of € 140,442 (▼ 25% vs 2024). filed late Source: NBB ↗
Jan 3, 2017 New establishment in Edegem. KBO
2017 Carolien Van Assche became a director. NBB
Jan 3, 2017 Start of the company according to the CBE. KBO

In short

From € 118,076 profit in 2022 to € 140,442 profit in 2025.

Paid € 256,481 in corporate taxes since 2022.

Best year ever: 2023, with € 212,493 profit.

Original PDFs at the National Bank ↗

A new publication or filing at Farma&Cie? We notify you, reason included.

Follow Farma&Cie

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Carolien Van Assche

Farma&Cie

Apotheek Van Assche 100%

Apotheek Smet & Van Assche 49.1%

Behind Farma&Cie is Carolien Van Assche. It owns 100% of Apotheek Van Assche and 49.1% of Apotheek Smet & Van Assche itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Carolien Van Assche

Director

Also active at: APOTHEEK SMET & VAN ASSCHE, Apotheek Van Assche

since 2017

Establishments

Establishment units

Physical locations of this company

Registered office

Ferdinand Verbiestlaan 41

2650 Edegem

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

PJB-Consulting

€ 33,081 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0668.680.188

VAT number

BE 0668.680.188

Registered office

Ferdinand Verbiestlaan 41, 2650 Edegem

Names & denominations

Farma&Cie

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

3 January 2017

Peppol

Active · Active since 26 Nov 2025

Activities · NACE

Activiteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

Farma&Cie

Warning lights

Financials

What happened to Farma&Cie?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions